James E. Lingeman is internationally acclaimed for his clinical expertise and research in kidney stone disease and holmium laser treatment of prostatic hypertrophy. Dr. Lingeman is an NIH funded investigator in the treatment of stone disease. Dr. Lingeman's extensive experience in lithotripsy and percutaneous surgery has earned him an international reputation as a leader in endourology. He is the founding director of the International Kidney Stone Institute.
Abstract
A retrospective review of patients undergoing flexible URS for renal stones only with subsequent CT scan within 3 months. Meticulous basketing of all stone fragments was performed whenever possible. A “true†zero-fragment stone-free rate was determined by reviewing the CT scan and radiologist's report. Patients with nephrocalcinosis (as determined by visual inspection of papilla at the time of URS) were assigned the “stone-free†category.